glp 1 glucose dependent insulin secretion GLP-1 promotes Frontiers | GLP-1 Receptor Agonists:

These findings are especially exciting because: Many patients with fibromyalgia are looking for alternatives to opioids

Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta4 fragment mechanism [5] [6]

Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels

Makes skin healthier, smoother, and brighter